December 27, 2017 – By Adrian Erickson

Investors sentiment increased to 1.25 in Q3 2017. Its up 0.05, from 1.2 in 2017Q2. It improved, as 20 investors sold INSYS Therapeutics, Inc. shares while 20 reduced holdings. 19 funds opened positions while 31 raised stakes. 18.21 million shares or 3.74% more from 17.56 million shares in 2017Q2 were reported.

Horizon Kinetics Limited Company holds 0.01% of its portfolio in INSYS Therapeutics, Inc. (NASDAQ:INSY) for 44,207 shares. California Public Employees Retirement owns 75,500 shares. Tower Cap Lc (Trc) has invested 0% of its portfolio in INSYS Therapeutics, Inc. (NASDAQ:INSY). Gam Holdg Ag reported 83,940 shares or 0.03% of all its holdings. Federated Investors Pa owns 1,168 shares or 0% of their US portfolio. Dimensional Fund Advsr L P reported 460,056 shares stake. 133,839 were reported by Goldman Sachs. 16,105 are owned by Amer Interest Group. Fincl Bank Of Mellon Corp invested in 0% or 158,021 shares. Macroview Ltd Limited Liability Company reported 100 shares. Moreover, Oz Lp has 0% invested in INSYS Therapeutics, Inc. (NASDAQ:INSY) for 88,800 shares. Deutsche Fincl Bank Ag reported 0% of its portfolio in INSYS Therapeutics, Inc. (NASDAQ:INSY). California State Teachers Retirement System has 0% invested in INSYS Therapeutics, Inc. (NASDAQ:INSY). Balyasny Asset Ltd Limited Liability Company holds 175,000 shares. State Board Of Administration Of Florida Retirement has 17,901 shares.

Insys Therapeutics (NASDAQ:INSY) Rating Reaffirmed

Insys Therapeutics (NASDAQ:INSY) just had their share rating of a ‘Buy’ issued by research analysts at Jefferies, who now has a $14.0 target on the $569.01M market cap company or a 80.41 % upside potential. This key information was shown in analysts report on Wednesday, 18 October.

Investors sentiment increased to 1.25 in Q3 2017. Its up 0.05, from 1.2 in 2017Q2. It improved, as 20 investors sold INSYS Therapeutics, Inc. shares

Read More Here...